Supernus Pharmaceuticals, Inc.
SUPN
$44.88
$1.563.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 165.45M | 149.82M | 174.16M | 175.69M | 168.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 165.45M | 149.82M | 174.16M | 175.69M | 168.33M |
| Cost of Revenue | 16.83M | 15.76M | 26.10M | 17.58M | 17.92M |
| Gross Profit | 148.63M | 134.06M | 148.06M | 158.11M | 150.41M |
| SG&A Expenses | 94.55M | 94.34M | 81.61M | 81.25M | 85.90M |
| Depreciation & Amortization | 20.82M | 19.79M | 18.24M | 19.49M | 20.11M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 154.31M | 156.82M | 154.60M | 147.36M | 150.11M |
| Operating Income | 11.14M | -7.00M | 19.56M | 28.33M | 18.21M |
| Income Before Tax | 16.67M | -5.83M | 26.38M | 44.94M | 26.30M |
| Income Tax Expenses | -5.83M | 6.00M | 11.05M | 6.45M | 6.39M |
| Earnings from Continuing Operations | 22.50M | -11.83M | 15.33M | 38.50M | 19.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.50M | -11.83M | 15.33M | 38.50M | 19.92M |
| EBIT | 11.14M | -7.00M | 19.56M | 28.33M | 18.21M |
| EBITDA | 32.50M | 13.39M | 38.41M | 48.43M | 38.93M |
| EPS Basic | 0.40 | -0.21 | 0.28 | 0.70 | 0.36 |
| Normalized Basic EPS | 0.17 | -0.03 | 0.28 | 0.37 | 0.25 |
| EPS Diluted | 0.40 | -0.21 | 0.27 | 0.69 | 0.36 |
| Normalized Diluted EPS | 0.17 | -0.03 | 0.27 | 0.36 | 0.25 |
| Average Basic Shares Outstanding | 56.02M | 55.86M | 55.47M | 55.15M | 54.98M |
| Average Diluted Shares Outstanding | 56.64M | 55.86M | 56.46M | 56.02M | 55.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |